Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Net Cash Flow (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Net Cash Flow for 11 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 118.64% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Dec 2025, down 152.67% year-over-year, with the annual reading at -$2.1 million for FY2025, 152.67% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$1.9 million at Marker Therapeutics, down from $7.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $43.2 million in Q1 2021, with the low at -$14.7 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $57457.0, with a median of -$3.7 million recorded in 2024.
  • The sharpest move saw Net Cash Flow surged 1282.69% in 2021, then crashed 134.01% in 2022.
  • Over 5 years, Net Cash Flow stood at -$5.2 million in 2021, then grew by 21.42% to -$4.1 million in 2022, then surged by 42.27% to -$2.4 million in 2023, then skyrocketed by 531.45% to $10.2 million in 2024, then crashed by 118.64% to -$1.9 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$1.9 million, $7.1 million, and -$1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.